Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1AT-home natalizumab treated MS patient
(D06886)		----[1] 13 💬
2Dosing interruption OF natalizumab
(D06886)		----[1] 13 💬
3Interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab
(D06886)		----[1] 13 💬
4Natalizumab
(D06886)		[1] Natalizumab[1] Natalizumab (D06886) 💬 [1] ITGA4 💬 [15] Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Cytoskeleton in muscle cells, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬[5] 13, 15, 25, 46, 96 💬
5Natalizumab 300 MG IN 15 ML injection
(D06886)		[1] Natalizumab[1] Natalizumab (D06886) 💬 [1] ITGA4 💬 [15] Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Cytoskeleton in muscle cells, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬[1] 13 💬
6Natalizumab discontinuation
(D06886)		[1] Natalizumab[1] Natalizumab (D06886) 💬 [1] ITGA4 💬 [15] Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Cytoskeleton in muscle cells, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬[1] 13 💬
7Natalizumab FOR IV infusion
(D06886)		[1] Natalizumab[1] Natalizumab (D06886) 💬 [1] ITGA4 💬 [15] Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Cytoskeleton in muscle cells, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬[1] 13 💬
8Natalizumab FOR subcutaneous injection
(D06886)		[1] Natalizumab[1] Natalizumab (D06886) 💬 [1] ITGA4 💬 [15] Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Cytoskeleton in muscle cells, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬[1] 13 💬
9Natalizumab IV
(D06886)		[1] Natalizumab[1] Natalizumab (D06886) 💬 [1] ITGA4 💬 [15] Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Cytoskeleton in muscle cells, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬[1] 13 💬
10Natalizumab SC
(D06886)		[1] Natalizumab[1] Natalizumab (D06886) 💬 [1] ITGA4 💬 [15] Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Cytoskeleton in muscle cells, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬[1] 13 💬
11Natalizumab treatment
(D06886)		[1] Natalizumab[1] Natalizumab (D06886) 💬 [1] ITGA4 💬 [15] Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Cytoskeleton in muscle cells, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬[1] 13 💬
12Natalizumab/natalizumab-sztn, alemtuzumab, ocrelizumab, rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, cladribine, ofatumumab, ublituximab-xiiy, ocrelizumab and hyaluronidase-ocsq
(D06886)		[1] Natalizumab[1] Natalizumab (D06886) 💬 [1] ITGA4 💬 [15] Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Cytoskeleton in muscle cells, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬[1] 13 💬
13Personalized extended interval dosing OF natalizumab
(D06886)		----[1] 13 💬